­
­
­
­

Inventi Impact: Biomedical Imaging

Articles

  • Inventi:ebmi/29540/19
    Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal 18F-FES PET/CT
    Research 2019 : October - December
    SiMin He, MingWei Wang, YongPing Zhang, JianMin Luo, YingJian Zhang

    Endocrine monotherapy of breast cancers is generally hampered by the primary/acquired resistance and adverse sides in clinical\nsettings. Herein, advantaging the multitargeting antitumor effects and normal organ-protecting roles of Chinese herbal medicine,\nthe aim of this study was to investigate the enhanced synergistic efficacy of fulvestrant plus Tan IIA combination therapy in ERpositive\nbreast cancers and to monitor the early response by longitudinal...............

    How to Cite this Article
    Attribution/ CC Compliant Citation: He, SiMin, et al.\n\"Monitoring the Early Response of Fulvestrant Plus\nTanshinone IIA Combination Therapy to Estrogen Receptor-\nPositive Breast Cancer by Longitudinal 18F-FES PET/CT.\"\nContrast Media & Molecular Imaging 2019 (2019).\nhttps://doi.org/10.1155/2019/2374565\nhttp://creativecommons.org/licenses/by/4.0/\n\nSome formatting elements, header, footer, logos, dates and\npagination were modified while adapting this article.
    Download Full Text